Compare iShares MSCI India ETF (INDA) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI India ETF vs TG Therapeutics Inc — how do they compare? iShares MSCI India ETF trades at $48.78, while TG Therapeutics Inc trades at $54.07 (market cap $8.26B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals.
| INDA | TGTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $55.29 | $59.06 |
52-Week Low | $45.42 | $26.39 |
Market Cap | — | $8.26B |
Enterprise Value | — | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDA trades at $48.56, down 0.72% on the day, with neutral technical signals overall. The ETF shows bullish moving averages but neutral oscillators, with key support and resistance clustered around $49. Recent news highlights India's strong 7.8% GDP growth (CNBC, 2026-06-05) and ongoing comparisons with other India-focused ETFs amid foreign investor outflows.
The outlook remains mixed: India's robust economic expansion and strategic sector composition offer growth potential, but risks include geopolitical tensions, AI investment underperformance, and regulatory changes in clean energy. Analyst sentiment is cautiously optimistic, with some seeing value in INDA's discount to S&P 500 valuations.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% on the day, with mixed technical signals showing a neutral overall trend. The company demonstrates strong profitability with 65.95% net income margin and 112.6% ROE, though recent earnings have missed expectations in two of the last three quarters. Positive clinical developments for Briumvi in multiple sclerosis and schizophrenia trials provide growth catalysts, while a shareholder investigation presents near-term uncertainty.
The outlook remains cautiously optimistic with 84.6% analyst buy ratings but a consensus price target of $48.50 below current levels. Key opportunities include Briumvi's expanding indications and strong revenue growth, while risks involve clinical trial outcomes, the ongoing legal investigation, and premium valuations with P/E of 19.2 and P/S of 12.6.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
